From: HIV care in Yangon, Myanmar; successes, challenges and implications for policy
Variable | All n = 2643 | Died n = 151a | Alive on ART n = 2381a | p^ |
---|---|---|---|---|
Age | 37 (31–44) | 40 (33–45) | 37 (31–44) | 0.001 |
Gender (% male) | 1494 (57%) | 96 (64%) | 1327 (56%) | 0.06 |
Unemployed | 917 (35%) | 64 (42%) | 814 (34%) | 0.04 |
Living in a different regionb | 526 (20%) | 43 (30%) | 462 (20%) | 0.005 |
CD4 + count at registration (cells/mm3) | 169 (59–328) | 45 (23–127) | 183 (65–337) | <0.001 |
WHO stage at registration | 3 (3–3) | 4 (3–4) | 3 (2–3) | 0.0001 |
On treatment for tuberculosis | 1124 (43%) | 99 (66%) | 971 (41%) | <0.001 |
Isoniazid prophylaxis therapyc | 21 (0.8%) | 0 | 20 (0.8%) | 0.26 |
Co-trimoxazole prophylaxis therapyd | 2125 (81%) | 136 (93%) | 1904 (80%) | <0.001 |